Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000180112 | SCV000232488 | uncertain significance | not provided | 2014-05-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002054143 | SCV002404723 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2024-01-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002426861 | SCV002742010 | likely benign | Cardiovascular phenotype | 2019-12-13 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV004553021 | SCV004712591 | likely benign | JAG1-related disorder | 2023-11-01 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |